Bausch Health Companies (BHC) Shares Gap Down to $24.34
Bausch Health Companies Inc (NYSE:BHC) shares gapped down before the market opened on Thursday . The stock had previously closed at $24.88, but opened at $24.34. Bausch Health Companies shares last traded at $24.12, with a volume of 5951852 shares.
Several brokerages have issued reports on BHC. Zacks Investment Research cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. Royal Bank of Canada raised their price target on shares of Bausch Health Companies from $25.00 to $26.00 and gave the company a “hold” rating in a report on Wednesday, August 8th. Wells Fargo & Co restated a “sell” rating on shares of Bausch Health Companies in a report on Monday, August 6th. Piper Jaffray Companies set a $13.00 price target on shares of Bausch Health Companies and gave the company a “sell” rating in a report on Monday, July 23rd. Finally, ValuEngine upgraded shares of Bausch Health Companies from a “sell” rating to a “hold” rating in a report on Monday, September 24th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. Bausch Health Companies presently has a consensus rating of “Hold” and an average target price of $26.89.
The firm has a market cap of $8.97 billion, a price-to-earnings ratio of 6.44, a PEG ratio of 0.37 and a beta of -0.48. The company has a current ratio of 1.14, a quick ratio of 0.89 and a debt-to-equity ratio of 6.99.
In related news, CEO Joseph C. Papa bought 30,000 shares of the stock in a transaction that occurred on Friday, September 14th. The stock was bought at an average cost of $22.32 per share, for a total transaction of $669,600.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Schutter Richard U. De bought 125,000 shares of the stock in a transaction that occurred on Thursday, September 13th. The stock was bought at an average price of $23.96 per share, with a total value of $2,995,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 165,000 shares of company stock worth $3,890,700 over the last 90 days. Company insiders own 11.54% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in BHC. NEXT Financial Group Inc acquired a new stake in Bausch Health Companies in the 3rd quarter worth approximately $101,000. Baxter Bros Inc. acquired a new stake in Bausch Health Companies in the 3rd quarter worth approximately $408,000. Nexus Investment Management Inc. acquired a new stake in Bausch Health Companies in the 3rd quarter worth approximately $862,000. Point View Wealth Management Inc. acquired a new stake in Bausch Health Companies in the 2nd quarter worth approximately $1,132,000. Finally, Marshall Wace LLP acquired a new stake in Bausch Health Companies in the 2nd quarter worth approximately $2,974,000. Institutional investors own 43.16% of the company’s stock.
Bausch Health Companies Company Profile (NYSE:BHC)
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
See Also: What is the NASDAQ?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.